Cerus

Historical price data

Cerus Corporation is dedicated to becoming the preeminent global blood products company by safeguarding the world's blood supply through its INTERCEPT pathogen reduction technology. The company has achieved significant commercial traction with its FDA and CE-marked systems for platelets and plasma, and its U.S.-approved INTERCEPT Fibrinogen Complex. Its strategic focus is on expanding the INTERCEPT platform to all major blood components, most critically red blood cells, while driving global adoption through partnerships with blood centers and health authorities.

The INTERCEPT Blood System is a photochemical pathogen reduction platform that uses synthetic psoralen compounds and UVA light to inactivate a broad spectrum of pathogens and white blood cells in blood components by irreversibly cross-linking their nucleic acids.

Cerus's primary direct competitor is Terumo BCT's Mirasol PRT system, though Cerus holds a key advantage with FDA approval for platelets and plasma in the U.S. The larger competition is the entrenched standard of care of individual pathogen testing, requiring Cerus to demonstrate superior cost-effectiveness and clinical utility to drive adoption.